Roi Weiser, M.D.
Department of Surgical Oncology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Assistant Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Wellness Officer, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Program Director, Soft Tissue and GI Surgical Oncology Fellowship (aka International Surgical Oncology Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2011 | Tel-Aviv University, Tel-Aviv, IL, MD |
| 2006 | Tel-Aviv University, Tel-Aviv, IL, Health Sciences, BS |
| 2004 | Université Paris IV, La Sorbonne, FR, Maîtrise de Philosophie, MA |
| 2002 | Tel-Aviv University, Tel-Aviv, IL, Philosophy and English Literature, BA |
Postgraduate Training
| 2025-2025 | Leading Clinical Research Faculty Learning Series, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2022-2022 | MD Anderson Robotic D2 Gastrectomy Course, IGCC 2022 Pre-Congress Hands-On Course, Houston, Texas |
| 2021-2022 | Clinical Fellowship, Surgical Oncology (International program), University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2021 | Clinical Fellowship, Breast Surgical Oncology, University of Texas Medical Branch, Galveston, Texas |
| 2020-2020 | Oncoplastic Breast Surgery Course, American Society of Breast Surgery, University of Texas Medical Branch, Galveston, Texas |
| 2018-2019 | Advanced Teaching Strategies GME program, Tel-Aviv University, Tel-Aviv |
| 2016-2018 | Chief Resident, General Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv |
| 2012-2018 | Clinical Residency, General Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv |
| 2010-2011 | Clinical Internship, Tel-Aviv Sourasky Medical Center, Tel-Aviv |
Licenses & Certifications
| 2025 | Texas Medical Board License |
| 2023 | Texas Medical Board, Temporary Faculty License |
| 2020 | Texas Physician in Training Permit |
| 2018 | Israeli Board Certification in General Surgery |
| 2011 | Israeli Medical License |
Experience & Service
Faculty Academic Appointments
Faculty, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 2018 - 2020
Other Professional Positions
Lieutenant (Reserve Duty), Heliborne Search and Rescue Unit, Israeli Defense Force, 2014 - Present
Sergeant Major, Israeli Defense Force, 1994 - 1997
Extramural Institutional Committee Activities
Member, International Committee, The Society of Surgical Oncology, 2025 - Present
Member, Melanoma Committee, SWOG Cancer Research Network, 2025 - Present
Member, Surgery Committee, SWOG Cancer Research Network, 2025 - Present
Member, Education Executive Team, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Institutional Algorithms for Peri-op Management of Anticoagulation and Antiplatelet Agents Working Group, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Education Executive Committe, Surgical Oncology Department, 2024 - Present
Member, Breast Fellows' Working Groups, American Society of Breast Surgeons, 2021 - 2022
Member, Institutional Committee on Emergency Department Reorganization, Tel-Aviv Sourasky Medical Center, 2019 - 2020
Data Science and Quality Division, Institutional Committee on Artificial Intelligence and Physician Decision Support, Tel-Aviv Sourasky Medical Center, 2018 - 2020
Member, Institutional Committee on Nutritional Intervention, Tel-Aviv Sourasky Medical Center, 2018 - 2020
Honors & Awards
| 2025 | Ranked in top 10% nationally in patient care experience by the Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) satisfaction score for FY25 |
| 2024 | Ranked in top 1% nationally in patient care experience by the Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) satisfaction score for FY24 |
| 2021 | Outstanding Overall Fellow Nominee, University of Texas Medical Branch |
| 2020 | The Claire and E.G. Rosenblatt Oncologist Exchange Program Scholarship, Israel Cancer Association |
| 2012 | Excellence Award – Intern, Tel-Aviv Sourasky Medical Center |
| 2002 | Excellence Award & Scholarship for Venice International University Program, Venice International University |
| 2000 | The Becky Grunwald Award, Tel-Aviv University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Immunotherapy for Breast Cancer and Perioperative Considerations. Conference. CMC and BSO Education Conference. Houston, Texas, US.
- 2025. Multidisciplinary Care Discussion Panel. Panelist. Cancer Network Melanoma Hybrid Integration Retreat. Houston, Texas, US.
- 2025. Clinical Trails Course - Small Group Discussion. Panelist. Houston, Texas, US.
- 2025. Patient-Specific Computational Modeling from Pre-Treatment Biopsies Can Discern Pathologic Response to Neoadjuvant Immunotherapy in Patients with Stage III Melanoma. Poster. The Society of Melanoma Research International Conference. Houston, Texas, US.
- 2025. Immunotherapy for Breast Cancer and Preoperative Considerations. Conference. Breast Surgical Oncology Fellows’ Education Conference. Houston, Texas, US.
- 2024. Multidisciplinary Care Discussion Panel. Panelist. Cancer Network Melanoma Integration Retreat. Houston, Texas, US.
- 2024. Immunotherapy for Breast Cancer and Preoperative Considerations. Conference. Houston, TX, US.
- 2023. Multidisciplinary Care Discussion Panel. Panelist. Multidisciplinary Care Discussion Panel. Houston, TX, US.
- 2021. Fluoroscopic Intra-operative Neoplasm and Node Detection (FIND): a Quality Improvement Comparative Trial with Wire Localization Poster Presentation (Presenter). Poster. UTMB Health Graduate Medical Education Quality Improvement & Patient Safety Poster Session. Galveston, Texas, US.
Regional Presentations
- 2024. Regional Skills Course on Breast. Visiting. L-Star Galveston ACS Regional Oncoplastic Breast Course Visiting professorship (Faculty). Galveston, Texas, US.
- 2022. Efficacy of Fluoroscopic Intraoperative Neoplasm and Node Detection (FIND) Procedure Compared to Standard Wire Localization. Conference. Houston, Texas, US.
- 2021. The 21-gene Recurrence Score and Chemotherapy Use in Node Positive Invasive Lobular Carcinoma Patients: An NCDB Analysis. Conference. The 21-gene Recurrence Score and Chemotherapy Use in Node Positive Invasive Lobular Carcinoma Patients: An NCDB Analysis, TX, US.
National Presentations
- 2026. EP16. NRAS mutant melanoma is associated with response to Talimogene Laherparepvec (T-VEC) but not improved survival. Poster. Phoenix, Arizona, US.
- 2026. Neoadjuvant Pembrolizumab in Stage IIB/C Melanoma: Updated Clinical Outcomes and Translational Data from Phase 2 Trial NCT03757689 Session: Best Papers I. Poster. Phoenix, Arizona, US.
- 2025. A Prospective Single-Arm Trial of Postoperative 36 Gy in 10 Fractions for Merkel Cell Carcinoma. Conference. San Francisco, California, US.
- 2025. The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma Microsatellitosis. Conference. San Francisco, California, US.
- 2025. Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment. Poster. Chicago, Illinois, US.
- 2025. SWOG/Hope Foundation Impact Award Presentation. Poster. San Francisco, California, US.
- 2025. Immunotherapy Toxicities in the Preoperative Setting. Invited. Houston, TX, US.
- 2025. Real-world outcomes of patients with clinically node positive melanoma undergoing neoadjuvant immunotherapy and nodal dissection. Conference. Tampa, Florida, US.
- 2025. Nodal imaging concordance with pathologic findings after neoadjuvant immunotherapy in patients with Stage III melanoma. Conference. Tampa, Flordia, US.
- 2024. Minimally Invasive Tumor Tissue Procurement is Feasible for Clinical Manufacturing of OBX-115 Engineered Tumor-Infiltrating-Lymphocytes (TIL). Poster. Houston, Texas, US.
- 2024. Combination Radiotherapy and Immunotherapy for Patients Presenting with Locoregionally Advanced Anorectal Mucosal Melanoma. Poster. New Orleans, Louisiana, US.
- 2024. Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era. Poster. Washington, D.C, District of Columbia, US.
- 2024. Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma. Poster. Washington, D.C, District of Columbia, US.
- 2024. Adjuvant Primary RT for Melanoma in the Immunotherapy Era. Conference. Washington, D.C, District of Columbia, US.
- 2024. Delineating germline, molecular and microbiome factors driving mucosal melanoma risk and immunotherapy response. Conference. New Orleans, Louisiana, US.
- 2024. Adrenal Insufficiency in the Immunotherapy Era – Improving the Identification of At-Risk Patients Prior to Melanoma Surgery. Poster. Adrenal Insufficiency in the Immunotherapy Era – Improving the Identification of At-Risk Patients Prior to Melanoma Surgery. Altanta, GA, US.
- 2024. Avoiding Perioperative Adrenal Crisis. Invited. Steamboat Springs, Colorado, US.
- 2022. Intraoperative Fluoroscopy Obviates the Need for Second Procedure for Breast Lesion Localization. Conference. Intraoperative Fluoroscopy Obviates the Need for Second Procedure for Breast Lesion Localization. Palm Beach, FL, US.
- 2021. De-escalation of Endocrine Therapy in Early Hormone Receptor-Positive Breast Cancer: When is Local Treatment Enough?. Conference. De-escalation of Endocrine Therapy in Early Hormone Receptor-Positive Breast Cancer: When is Local Treatment Enough?, US.
- 2021. Fluoroscopic Intra-operative Neoplasm and Node Detection (FIND): A Comparative Trial with Needle Localization. Poster. Fluoroscopic Intra-operative Neoplasm and Node Detection (FIND): A Comparative Trial with Needle Localization, US.
- 2021. Lobular Cancer Responsiveness to Chemotherapy is Equivalent to Ductal Cancer with Similar Genomic Profiles: An NCDB Analysis. Poster. Lobular Cancer Responsiveness to Chemotherapy is Equivalent to Ductal Cancer with Similar Genomic Profiles: An NCDB Analysis, US.
- 2021. Prognosis and Chemotherapy Use in Breast Cancer Patients with Single and Multiple Lymphatic Micrometastases: An NCDB Analysis. Conference, US.
- 2020. Characterizing the Breast Cancer Microbiome. Conference, US.
- 2016. Lymph Node Status and Patterns of Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Poster. Lymph Node Status and Patterns of Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Boston, MA, US.
International Presentations
- 2026. Case Presentation: Global Think Tank on Extramammary Paget’s Disease (EMPD). Invited. Prague, CZ.
- 2025. Patient-Specific Computational Modeling from Pre-Treatment Biopsies Can Discern Pathologic Response to Neoadjuvant Immunotherapy in Patients with Stage III Melanoma. Poster. Amsterdam, NL.
- 2025. Debate III: Do we need to re-operate all positive margins after BCS? – In favor. Invited. Jerusalem, IL.
- 2024. Combination TVEC and Immune Checkpoint Blockade in the Neoadjuvant Setting in Patients with Metastatic Melanoma. Conference. Australasian Melanoma Conference. Sydney, AU.
- 2024. Combination Radiotherapy and Immunotherapy for Patients Presenting with Locoregionally Advanced Anorectal Mucosal Melanoma. Poster. Australasian Melanoma Conference. Sydney, AU.
- 2024. Minimally Invasive Tumor Tissue Procurement is Feasible for Clinical Manufacturing of OBX-115 Engineered Tumor-Infiltrating-Lymphocytes (TIL). Poster. Vancouver, CA.
- 2022. Completion Lymphadenectomy in Melanoma. Invited. Completion Lymphadenectomy in Melanoma, IL.
- 2019. Exploring Novel Combinatorial Treatments for Colorectal Cancer Using an Ex-vivo Organ Culture Method. Oral Presentation. Conference. Exploring Novel Combinatorial Treatments for Colorectal Cancer Using an Ex-vivo Organ Culture Method. Oral Presentation, IL.
- 2018. Adnexal Carcinomas: Experience of a Tertiary Center. Poster. Barcelona, ES.
- 2017. Adnexal Carcinomas: Experience of a Tertiary Center. Conference. Adnexal Carcinomas: Experience of a Tertiary Center, IL.
- 2016. Lymph Node Status and Patterns of Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Conference. Lymph Node Status and Patterns of Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma, IL.
- 2015. Management of Endoscopic Retrograde Cholangiopancreatography Related Perforations. Conference. Management of Endoscopic Retrograde Cholangiopancreatography Related Perforations, IL.
- 2013. Surveillance of Hepatocellular Carcinoma in Israel. Conference. Surveillance of Hepatocellular Carcinoma in Israel, IL.
- 2012. The Prognostic Significance of Rising Serum CA-125 Levels within the Normal Range in Patients with Epithelial Ovarian, Tubal and Primary Peritoneal Carcinoma after Complete Clinical Response to Primary Therapy. Poster. Tel Aviv, IL.
Formal Peers
- 2024. Fundamentals of Oncoplastic Breast Surgery Surgical Skills Course, Faculty. Galveston, Texas, US.
- 2023. Fluoroscopic Intraoperative Neoplasm and Node Detection. Visiting, US.
Grant & Contract Support
| Date: | 2026 - 2028 |
| Title: | Response to neoadjuvant immunotherapy in the nodal basins of patients with melanoma: laying the groundwork for de-escalating lymphatic surgery |
| Funding Source: | Institutional Research Grant |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Evaluating the Nodal Basin of Patients with Melanoma Treated in the Neoadjuvant Arm of SWOG S1801 to Identify Predictors of Prognosis and Response |
| Funding Source: | SWOG/Hope Foundation Impact Award |
| Role: | PI |
| Date: | 2025 - 2027 |
| Title: | PRISAM: Preoperative Radiotherapy & Immunotherapy for Sinonasal & Anorectal Melanoma: Proof of Concept for a Noel Paradigm to Promote Disease Control, Organ Preservation & QOL |
| Funding Source: | Multidivisional Shark Tank Award |
| Role: | Co-PI |
| Date: | 2024 - 2026 |
| Title: | Immediate Lymphatic Reconstruction after Lymphadenectomy in Melanoma ( |
| Funding Source: | Survivorship IRG |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Devireddy A, Yi Y, Nordlund KN, Lin R, Salem A, Yang NX, Keatts S, Jerez O, Farooqi A, Bishop AJ, Ashleigh Guadagnolo B, Nagarajan P, Weiser R, Fisher SB, Goepfert R, Ross MI, Amaria RN, Glitza Oliva IC, Yoder AK, Mitra D. ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with Microsatellitosis. Ann Surg Oncol, 2026. e-Pub 2026. PMID: 42223772.
- Devireddy A, Yi Y, Nordlund KN, Lin R, Salem A, Yang NX, Keatts S, Jerez O, Farooqi A, Bishop AJ, Guadagnolo BA, Nagarajan P, Weiser R, Fisher SB, Goepfert R, Ross MI, Amaria RN, Oliva ICG, Yoder AK, Mitra D. The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis. Ann Surg Oncol, 2026. e-Pub 2026. PMID: 42189441.
- Amouzegar A, Wu X, Long JP, Chen GW, Wong JW, Prabhakaran S, Little L, Gumbs C, Bota N, Malke J, Simon J, Zhang J, Nagarajan P, Davies MA, Tawbi H, Amaria RN, Oliva ICG, Ikeguchi AP, Su S, Hanna EY, Weiser R, Bednarski B, Sims TT, Mitra D, Wargo J, Gershenwald JE, Scheet P, Yu Y, Huff C, Nelson KC, McQuade JL, Futreal PA. Germline variants in cancer susceptibility genes among patients with mucosal melanoma. NPJ Genom Med, 2026. e-Pub 2026. PMID: 42177185.
- Herb J, Bassett RL, Torres-Cabala CA, Prieto VG, Patel SP, Holder AM, Fisher SB, Lucci A, Wargo J, Amaria RN, Davies MA, Glitza Oliva IC, Tawbi HA, McQuade J, Ikeguchi AP, Wong MK, Diab AK, Gershenwald JE, Ross MI, Weiser R. Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection. Ann Surg Oncol, 2026. e-Pub 2026. PMID: 41838361.
- Yang NX, Rosamilia GL, Arifin AJ, Salem AF, Yoder AK, Keatts SA, Jerez O, Lin R, Bishop AJ, Farooqi AS, Weiser R, Ross MI, Mericli AF, Guadagnolo BA, Goepfert RP, Mitra D. Surgical Reconstruction Toxicity Following Hypofractionated Adjuvant Radiotherapy for Primary Cutaneous Melanoma. Pract Radiat Oncol, 2025. e-Pub 2025. PMID: 41380909.
- Nelson N, Den J, Weiser R, Digbeu B, Silva HC, Robinson AS, Poselman F, Klimberg VS. The Era "or Error" of Second Localization Procedures. Breast J 2025:6391905, 2025. e-Pub 2025. PMID: 41059021.
- Keatts SA, Salem AF, Swanson DM, Farooqi AS, Bishop AJ, Amaria RN, McQuade JL, Glitza IC, Diab A, Weiser R, et al. Durable Local Control with Hypofractionated Radiation Therapy for Unresectable or Metastatic Melanoma. Clin Transl Radiat Oncol 49(100856), 2024. PMID: 29208633.
- Wanis KN, Kuerer HM, Sun SX, Hunt KK, Glencer AC, Teshome M, Lucci A, Weiser R, Johnson H, Smith BD, Gutierrez AM, Shaitelman SF, Arun BK. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open 7(6):e2418486, 2024. e-Pub 2024. PMID: 38916888.
- Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Outcomes of Patients with Resected Stage III/IV Acral or Mucosal Melanoma, Treated with Adjuvant Anti-PD-1 Based Therapy. Eur J Cancer 199:113563, 2024. e-Pub 2024. PMID: 38278007.
- Halfteck GG, Polychronopoulou YE, Haque W, Weiser R, Hatch SS, Klimberg VS. De-escalation of Post-mastectomy Irradiation in Hormone Receptor-Positive Breast Cancer with One to Three Positive Nodes. Ann Surg Oncol 30(13):8335-8343, 2023. e-Pub 2023. PMID: 37679538.
- Weiser R, Manno GC, Cass SH, et al. Fluoroscopic Intra-operative Breast Neoplasm and Node Detection (FIND). J Am Coll Surg 236(4):575-585, 2023. e-Pub 2023.
- Ho JJ, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, et al. Neoadjuvant Checkpoint Inhibitor Immunotherapy for Resectable Mucosal Melanoma. Front Oncol:1001150, 2022. e-Pub 2022.
- Weiser R, Polychronopoulou E, Hatch SS, Haque W, Ghani HA, He J, Kuo YF, Gradishar WJ, Klimberg VS. Adjuvant Chemotherapy in Patients with Invasive Lobular Carcinoma and Use of the 21-gene Recurrence Score: A National Cancer Database Analysis. Cancer 128(9):1738-1747, 2022. e-Pub 2022. PMID: 35137951.
- Gavert N, Zwang Y, Weiser R, et al. Ex Vivo Organotypic Cultures for Synergistic Therapy Prioritization Identify Patient-specific Responses to Combined MEK and Src Inhibition in Colorectal Cancer. Nat Cancer 3(2):219-231, 2022. e-Pub 2022.
- Weiser R, Polychronopoulou E, Haque W, et al. Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: an NCDB Analysis. Ann Surg Oncol 28(13):8717-8727, 2021. e-Pub 2021.
- Weiser R. Klimberg VS. ASO Author Reflections: Breast Cancer: What is in a Positive Node?. Ann Surg Oncol 28(13):8728, 2021. e-Pub 2021.
- Menes TS, Golan O, Weiser R, Tvito Green R. ASO Author Reflections: Facing the Challenge of the Missing clip in Breast Lumpectomy Specimens. Ann Surg Oncol 28(9):4981-4982, 2021. e-Pub 2021.
- Green RT, Weiser R, Golan O, Menes TS. In Search of the Lost Clip: Outcome of Women after Needle Guided Lumpectomy of a Marking Clip. Ann Surg Oncol 28(9):4974-4980, 2021. e-Pub 2021.
- Weiser R, Polychronopoulou E, Kuo YF, et al. De-escalation of Endocrine Therapy in Early Hormone Receptor-Positive Breast Cancer: When is Local Treatment Enough?. Ann Surg 274(4):654-663, 2021. e-Pub 2021.
- Weiser R, Haque W, Polychronopoulou E, et al. The 21-Gene Recurrence Score in Node-Positive, Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Cautionary Tale from an NCDB Analysis. Breast Cancer Res Treat 185(3):667-676, 2021. e-Pub 2021.
- Pencovich N, Nevo N, Weiser R, et al. Postoperative Rise of Circulating Mitochondrial DNA is Associated with Inflammatory Response in Patients Following Pancreaticoduodenectomy. Eur Surg Res 62(1):18-24, 2021. e-Pub 2021.
- Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, et al. The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria. Science 368(6494):973-980, 2020. e-Pub 2020.
- Weiser R, Pencovich N, Mlynarsky L, et al. Management of Endoscopic Retrograde Cholangiopancreatography – Related Perforations: Experience of a Tertiary Center. Surgery 161(4):920-929, 2017. e-Pub 2017.
- Papoulas M, Weiser R, Rosen G, et al. Visceral Fat Content Correlates with Retroperitoneal Soft Tissue Sarcoma (STS) Local Recurrence and Survival. World J Surg 39(8):1895-901, 2015. e-Pub 2015.
- Levy T, Weiser R, Boaz M, et al. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol 129(1):165-8, 2013. e-Pub 2013.
- Levy T, Weiser R, Boaz M, et al. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal and tubal cancers, who, after initial treatment, had a complete clinical response. Int J Gynecol Cancer(8):1344-8, 2012. e-Pub 2012.
Review Articles
- Seldomridge AN, Weiser R, Holder AM. Systemic Therapy for Melanoma: What Surgeons Need to Know. Surg Oncol Clin N Am 34(3):359-374, 2025. e-Pub 2025. PMID: 40413004.
- Newcomer K, Robbins K, Perone J, Hinojosa FL, Chen D, Jones S, Kaufman C, Weiser R, Fields R, Tyler D. Malignant Melanoma: Evolving Practice Management in an Era of Increasingly Effective Systemic Therapies. Curr Probl Surg 59(1):101030, 2022. e-Pub 2022.
Other Articles
- Herb J, Bassett RL, Torres-Cabala CA, Prieto VG, Patel SP, Holder AM, Fisher SB, Lucci A, Wargo J, Amaria RN, Davies MA, Glitza Oliva IC, Tawbi HA, McQuade J, Ikeguchi AP, Wong MK, Diab AK, Gershenwald JE, Ross MI, Weiser R Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection. Ann Surg Oncol, 2026. PMID: 42032252.
Abstracts
- Amouzegar A, Wu X, Long JP, Chen GW, Wong JW, Prabhakaran S, Little L, Gumbs C, Bota N, Malke J, Simon J, Zhang J, Nagarajan P, Davies MA, Tawbi H, Amaria RN, Glitza Oliva IC, Ikeguchi AP, Su S, Hanna EY, Weiser R, Bednarski B, Sims TT, Mitra D, Futreal P. Germline variants in cancer susceptibility genes among patients with mucosal melanoma, 2026. e-Pub 2026.
- Farooq MS, Lee A, Wang G, Mitnick S, Gimotty P, Vargas GM, Simons RA, Miura JT, Mitchell TC, Amaravadi RK, Schuchter LM, Xu X, Davies MA, Amaria RN, Chesney JA, Weiser R, Gershenwald JE, McMasters KM, Huang AC, Karakousis GC. Neoadjuvant Pembrolizumab in Stage IIB/C Melanoma: Updated Clinical Outcomes and Translational Data from Phase 2 Trial NCT03757689. Podium Presentation at the Society of Surgical Oncology Annual Meeting.
- Keatts S, Swanson D, Farooqi A, Bishop A, Amaria R, McQuade J, Glitza I, Diab A, Weiser R, Fisher S, Ross M, Guadagnolo B, Mitra D. Adjuvant Primary RT for Melanoma in the Immunotherapy Era. ASTRO Conference.
- Keatts S, Swanson D, Farooqi A, Bishop A, Amaria R, McQuade J, Glitza I, Diab A, Weiser R, Weiser R, Fisher S, Ross M, Guadagnolo B, Mitra D. Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era. ASTRO Conference.
- Damania A, Nagarajan P, Prabhakaran S, Bot N, Knafl M, Chu R, Sahasrabhojane P, Hoballah Y, Mitra D, Weiser R, Su S, Hanna E, Esmaeli B, Sims T, Pettaway C, Amaria R, Glitza Oliva I, Losh J, Ajami N, Woodman S, Wargo J, Futreal A, Vellano C, Heffernan T, Giuliani V. Delineating germline, molecular and microbiome factors driving mucosal melanoma risk and immunotherapy response. Society for Melanoma Research 21st International Congress.
- Keatts S, Swanson D, Farooqi A, Bishop A, Amaria R, McQuade J, Glitza I, Diab A, Weiser R, FIsher S, Ross M, Guadagnolo B, Mitra D. Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma. ASTRO Conference.
- Mitra D, Lin R, Farooqi A, Bishop A, Yoder A, Pearlnath C, Kol S, Weiser R, Goepfert R, Glitza I, Ross M, Wong M, Guadagnolo B. A Prospective Single-Arm Trial of Postoperative 36 Gy in 10 Fractions for Merkel Cell Carcinoma. American Society for Radiation Oncology (ASTRO).
- Nordlund K, Devireddy A, Lin R, Salem A, Yang N, Keatts S, Farooqi A, Bishop A, Guadagnolo B, Weiser R, Fisher S, Goepfert R, Ross M, Amaria R, McQuade J, Glitza I, Yoder A, Mitra D. The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma Microsatellitosis. American Society for Radiation Oncology (ASTRO).
Book Chapters
- Weiser R, You YN. Surgical Principals. In: In: Foote: Gunderson and Tepper's Clinical Radiation Oncology. 6th edition, 2026.
- Weiser R, Klimberg VS, Hunt KK. Diseases of the Breast. In: In: Tyler’s Sabiston Textbook of Surgery. 22nd edition, 2025.
- Weiser R, Lymphatic Mapping KV, Lymphadenectomy S. In: Cameron JL and Cameron AM (eds.). Current Surgical Therapy, 14th edition, 2023.
- Weiser R, Spiquel L, Singhal D, Klimberg VS. Lymphedema Prevention and Treatment: Axillary Reverse Mapping, LYMPHA, and Lympho Node Transfer. In: In: Bland KI, Copeland EM, Klimberg VS, Gradishar WJ (eds.). 6th Edition. The Breast, 2023.
- Weiser R, Berman RS, Gershenwald. Wide Excision of Primary Cutaneous Melanoma. In: In: Sabel MS, Mulholland MW (eds.). 2nd Edititon, 2023.
- Weiser R, You. Surgical Principals. In: Foote: Gunderson and Tepper's Clinical Radiation Oncology. 6th Edtion.
- Weiser R, Klimberg VS, Hunt KK. Diseases of the Breast. In: Tyler’s Sabiston Textbook of Surgery. 22nd edition.
- Weiser R, Klimberg VS. In: In: Chu QD, Klimberg VS, Anderson B, Balch C, Parker C, Dedey F, Mendez J, and Are C (eds.). A Practical Guide to Managing Breast Cancer for Low-Middle Income Countries.
Letters to the Editor
- Weiser R, Polychronopoulou E, Klimberg VS. Reply to “the use of national datasets to evaluate outcomes for invasive lobular carcinoma. Cancer 128: 3418-3419, 2022.
Patient Reviews
CV information above last modified June 19, 2026